comparisonThe table below summarizes the three major developments in peptide news November 2026, including regulatory changes, metabolic peptide advances, and neuroprotective breakthroughs. FDA 503B …
Source: realpeptides.coOpen reference →comparisonSeptember 2026 peptide news included significant formulation breakthroughs, particularly oral bioavailability improvements and novel delivery mechanisms. The table below compares leading pe…
Source: realpeptides.coOpen reference →comparisonThe following table summarises the three major categories of peptide-related developments reported in April 2026, comparing regulatory changes, clinical trial outcomes, and supply chain shi…
Source: realpeptides.coOpen reference →comparisonPurity Standard ≥95% via HPLC; ≥98% for Real Peptides products ≥98% via HPLC + USP monograph compliance Research: HPLC certificate sufficient; Clinical: Full USP validation required In vitr…
Source: realpeptides.coOpen reference →comparisonTriple GLP-1/GIP/Glucagon Agonists Retatrutide, Mazdutide Multi-receptor activation: GLP-1 (satiety), GIP (insulin secretion), glucagon (lipolysis, thermogenesis) TRIUMPH-1 Phase III: 24.2%…
Source: realpeptides.coOpen reference →comparisonMetabolic & Obesity Research Survodutide, mazdutide, and retatrutide Phase 3 results published; FDA provisional approval expected Q2 2027 GLP-1 agonists, dual- and triple-receptor agonists,…
Source: realpeptides.coOpen reference →